^
Association details:
| Biomarker: | FLT3‐ITD + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML co-mutations or a high FLT3–internal tandem duplication allelic ratio
Published date:
01/05/2021
Excerpt:
Analysis of 361 patients with FLT3‐mutated relapsed/refractory AML identified four major co‐mutation cohorts, each with ≥10% of patients: nucleophosmin 1 (NPM1, n = 173; 47·9%), DNA methyl transferase 3 alpha (DNMT3A, n = 115; 31·9%), DNMT3A/NPM1 (n = 86; 23·8%) and Wilms tumour 1 (WT1, n = 65; 18·0%)...The gilteritinib arm had superior response rates and overall survival across all four major co‐mutation cohorts, with the greatest survival benefit in patients with DNMT3A/NPM1 co‐mutation positivity...
